Amicus Therapeutics (FOLD) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The upward trend in estimate revisions for this pharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings ...

Amicus Therapeutics (FOLD) announced that it has signed a licensing agreement with Teva Pharmaceuticals (TEVA) , which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold (migalastat) 123 mg capsules before the related patents expired. The stock jumped 14% on Thursday as investors cheered the dispute settlement with TEVA. Galafold, Amicus' lead marketed drug, is the fir ...

Amicus Therapeutics (FOLD) shares ended the last trading session 14% higher at $11.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.8% loss over the past four weeks. The sudden rise in the stock price was observed after Amicus announced signing a licensing agreement with Teva Pharmaceuticals which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new dr ...

PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Amicus in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of GALAFOLD® (migalastat) 123mg capsules prior to expiration of the applicable patents. Pursua ...

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia. Poster Session: Pompe Disease Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P) P ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum. Shares of Amicus Therapeutics (NASDAQ: FOLD ) are stuck in a trading ra ...

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Thursday, September 5, 2024, at 10:00 a.m. ET Cantor Global Healthcare Conference 2024 in New York, NY on Tuesday, September 17, 2024, at 1:55 p.m. ET A live audio webcast of each presentation can also be accessed via the ...

PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Thursday, September 5, 2024, at 10:00 a.m. ET Cantor Global Healthcare Conference 2024 in New York, NY on Tuesday, September 17, 2024, at 1:55 p.m. ET A live audio webcast of each presentation can also be accessed via the i ...

Amicus Therapeutics, Inc.'s (FOLD) lead marketed drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has witnessed a strong sales uptake driven by continued demand. Sales of Galafold have been rising consistently over the past years. In the first six months of 2024, the drug generated sales worth $210.2 million, which increased 17% year over year at a constant currency basis. Galafold is currently approv ...

NicoElNino/iStock via Getty Images Amicus Therapeutics, Inc. (NASDAQ:FOLD) focuses on rare and orphan diseases, particularly Fabry and Pompe. The company's portfolio includes Galafold and Pombiliti. Notably, Galafold is an oral treatment that seems effective for Fabry by stabilizing the dysfunctional enzyme alpha-Gal A. FOLD's Pombiliti is a combination therapy with Opfolda, indicated for Pompe disease. Pombiliti replaces and stabilizes deficient or dysfunctional GAA enzymes needed for glycogen breakdown, h ...